Development of imatinibmesylate-induced interstitial lung disease 2 weeks after discontinuation of the treatment: a case report

BACKGROUND: Imatinibmesylate (imatinib) is a small molecule tyrosine kinase inhibitor administered to patients with chronic myelogenous leukemia and gastrointestinal stromal tumor. Although imatinib-associated interstitial lung disease is uncommon, a few cases have been reported so far. However, in...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakashima, Shota, Kakugawa, Tomoyuki, Motomura, Hiroko, Hirano, Katsuji, Sasaki, Eisuke, Nagata, Yasuhiro, Kinoshita, Akitoshi, Sakamoto, Noriho, Ishimatsu, Yuji, Mukae, Hiroshi, Kohno, Shigeru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3537559/
https://www.ncbi.nlm.nih.gov/pubmed/23174134
http://dx.doi.org/10.1186/2049-6958-7-48

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3537559/
https://www.ncbi.nlm.nih.gov/pubmed/23174134
http://dx.doi.org/10.1186/2049-6958-7-48

Ejemplares similares